Drug profile · INN
daunorubicin citrate
DAUNOXOME
daunorubicin citrate (DAUNOXOME) is a dna topoisomerase ii alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — daunorubicin citrate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
daunorubicin citrate (DAUNOXOME) is a dna topoisomerase ii alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase II alpha inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daunorubicin citrate?
daunorubicin citrate (DAUNOXOME) is a dna topoisomerase ii alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daunorubicin citrate?
DAUNOXOME is a marketed brand name for daunorubicin citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daunorubicin citrate?
daunorubicin citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.